Clinical trials · Raleigh–Durham, NC
Myelofibrosis clinical trials in Raleigh–Durham
We’re tracking 8 recruiting myelofibrosis studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06351631RecruitingPhase 3
Long-term safety study of bomedemstat for blood cancers
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
Durham, North CarolinaAges 18 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Durham, North CarolinaAges 18 years+ - NCT07623161RecruitingPhase 3
Elritercept versus placebo for myelofibrosis anemia on ruxolitinib
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Durham, North CarolinaAges 18 years+ - NCT04176198RecruitingPhase 1/Phase 2
Oral nuvisertib for myelofibrosis after JAK inhibitor failure
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Durham, North CarolinaAges 18 years+ - NCT06479135RecruitingPhase 3
Study of new drug added to ruxolitinib for myelofibrosis
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Durham, North CarolinaAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chapel Hill, North CarolinaAges 13 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Chapel Hill, North CarolinaAges 18–66
Hear when a new Myelofibrosis trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Myelofibrosis trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting myelofibrosis studies listed above.
- Duke Cancer Center · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- Duke Cancer Institute
- Duke University
- Duke University Medical Center
- Massive Bio SYNERGY-AI site
What taking part in a myelofibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting myelofibrosis studies in North Carolina.
Common questions
- Are there myelofibrosis clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 8 recruiting myelofibrosis studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myelofibrosis study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myelofibrosis studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.